Top
Main
 
All Outcomes
 
Feedback
Home
c19early.org COVID-19 treatment researchBromhexineBromhexine (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta
Home Adoption Other Treatments
@CovidAnalysis
Loading...
Analgesics⏵
Antiandrogens⏵
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Molnupiravir
Monoclonals⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins⏵
More⏵

Supplementary Data — Bromhexine for COVID-19: real-time meta analysis of 7 studies

@CovidAnalysis, April 2024, Version 22V22
Post
Share
PDF
Studies
Feedback
https://c19early.org/bmeta.html
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Ansarin (RCT) 91% 0.09 [0.01-1.59] 24mg death 0/39 5/39 Improvement, RR [CI] Dose (1d) Treatment Control Ansarin (RCT) 89% 0.11 [0.01-0.84] 24mg ventilation 1/39 9/39 Ansarin (RCT) 82% 0.18 [0.04-0.77] 24mg ICU 2/39 11/39 Vila Méndez (RCT) 67% 0.33 [0.01-7.94] 48mg oxygen 0/98 1/93 Vila Méndez (RCT) 67% 0.33 [0.01-7.94] 48mg hosp. 0/98 1/93 Vila Méndez (RCT) 71% 0.29 [0.03-2.68] 48mg no recov. 1/52 3/45 Vila Méndez (RCT) -187% 2.87 [0.12-68.6] 48mg no recov. 1/52 0/45 Vila Méndez (RCT) -7% 1.07 [0.64-1.77] 48mg viral load 98 (n) 93 (n) Vila Méndez (RCT) 17% 0.83 [0.41-1.66] 48mg viral load 98 (n) 93 (n) Vila Méndez (RCT) -41% 1.41 [0.71-2.80] 48mg viral load 98 (n) 93 (n) Vila Méndez (RCT) 13% 0.87 [0.68-1.11] 48mg viral+ 52/98 57/93 Vila Méndez (RCT) -14% 1.14 [0.94-1.37] 48mg viral+ 73/98 61/93 Li (RCT) 75% 0.25 [0.05-1.35] 96mg no disch. 2/12 4/6 Li (RCT) 50% 0.50 [0.09-2.73] 96mg oxygen 2/12 2/6 Mareev (RCT) 11% 0.89 [0.65-1.22] 32mg no recov. 33 (n) 33 (n) CT​1​ Mareev (RCT) 39% 0.61 [0.14-0.97] 32mg no recov. 14/24 20/21 CT​1​ Mareev (RCT) 8% 0.92 [0.77-1.09] 32mg hosp. time 33 (n) 33 (n) CT​1​ Mareev (RCT) 87% 0.13 [0.01-2.25] 32mg viral+ 0/17 3/13 CT​1​ Tolouian (RCT) 76% 0.24 [0.01-8.03] 32mg death 48 (n) 52 (n) Tolouian (RCT) 76% 0.24 [0.01-7.69] 32mg no improv. 48 (n) 52 (n) Tolouian (RCT) -75% 1.75 [1.13-2.71] 32mg viral+ 29/48 18/52 Mikhaylov (RCT) 80% 0.20 [0.01-3.97] 24mg hosp. 0/25 2/25 Mikhaylov (RCT) 91% 0.09 [0.01-1.56] 24mg symp. case 0/25 5/25 Mikhaylov (RCT) 71% 0.29 [0.07-1.24] 24mg cases 2/25 7/25 Tolouian (DB RCT) 33% 0.67 [0.04-10.5] 24mg death 0/187 1/185 Tolouian (DB RCT) 70% 0.30 [0.05-1.78] 24mg hosp. 1/187 6/185 Tolouian (DB RCT) 53% 0.47 [0.25-0.87] 24mg symp. case 16/187 34/185 Tolouian (DB RCT) 50% 0.50 [0.24-0.99] 24mg cases 13/187 26/185 Bromhexine COVID-19 outcomes c19early.org April 2024 ​1​ CT: study uses combined treatment Favors bromhexine Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0